Get started
Author

Allison Kaeding

Observed names: A. Kaeding, Allison J Kaeding, Allison J. Kaeding, Allison June Kaeding
OpenAlex ID: A5025650144
The natural history of soy allergy
2010 · Jessica H. Savage, Allison J. Kaeding, et al. · Journal of Allergy and Clinical Immunology · 226
PDF
BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study
2023 · Susan Bal, Myo Htut, et al. · Blood · 58
Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study
2022 · Susan Bal, M. Hakan Kocoglu, et al. · Blood · 38
Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia
2021 · Allison J. Kaeding, Sonali P. Barwe, et al. · Blood Advances · 38
PDF
Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)
2024 · Susan Bal, Larry D Anderson, et al. · Blood · 25
S193: Bms-986393 (cc-95266), a G Protein–coupled Receptor Class C Group 5 Member D (gprc5d)–targeted Car T-cell Therapy for Relapsed/refractory Multiple Myeloma (rrmm): Results From a Phase 1 Study
2023 · Susan Bal, Jesus Berdeja, et al. · HemaSphere · 15
Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies
2021 · Anilkumar Gopalakrishnapillai, Colin E. Correnti, et al. · Cancers · 13
PDF
BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results
2024 · Susan Bal, Myo Htut, et al. · Blood · 9
PDF
Immunotherapeutic Targeting of Mesothelin in Acute Myeloid Leukemia in Vitro with Anetumab Ravtansine and a Novel Antibody-Drug Conjugate
2018 · Allison Kaeding, Katherine Tarlock, et al. · Blood · 7
Discovery and Validation of Cell-Surface Protein Mesothelin (MSLN) As a Novel Therapeutic Target in AML: Results from the COG/NCI Target AML Initiative
2016 · Katherine Tarlock, Allison J. Kaeding, et al. · Blood · 7
Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma
2026 · Susan Bal, Myo Htut, et al. · Blood · 6
In Vivo Evaluation of Mesothelin As a Therapeutic Target in Pediatric Acute Myeloid Leukemia
2019 · Anilkumar Gopalakrishnapillai, Allison Kaeding, et al. · Blood · 5
Safety and biological activity of the FLT3 inhibitor lestaurtinib in infant MLL-rearranged (MLL-r) ALL: Children's Oncology Group protocol AALL0631.
2012 · Di Sun, Allison Kaeding, et al. · Journal of Clinical Oncology · 3
Mesothelin Is a Novel Disease Marker and Potential Therapeutic Target in Pediatric Acute Myeloid Leukemia
2017 · Allison Kaeding, Katherine Tarlock, et al. · Blood · 2
Mesothelin Targeting Bites for Pediatric AML: In Vivo Efficacy and Specificity
2019 · Anilkumar Gopalakrishnapillai, Colin Correnti, et al. · Blood · 1
POSTER: MM-1223: Arlocabtagene Autoleucel, a GPRC5D-Targeted CAR T-Cell Therapy for Patients With Relapsed/Refractory Multiple Myeloma: Updated Phase 1 Safety and Efficacy Results in Patients With 1–3 Prior Regimens
2026 · Susan Bal, Myo Htut, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-1119: Arlocabtagene Autoleucel in Patients With Heavily Pretreated Relapsed/Refractory Multiple Myeloma: Final Analysis From the Phase 1 Study
2026 · Susan Bal, Myo Htut, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-1223: Arlocabtagene Autoleucel, a GPRC5D-Targeted CAR T-Cell Therapy for Patients With Relapsed/Refractory Multiple Myeloma: Updated Phase 1 Safety and Efficacy Results in Patients With 1–3 Prior Regimens
2026 · Susan Bal, Myo Htut, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-1119: Arlocabtagene Autoleucel in Patients With Heavily Pretreated Relapsed/Refractory Multiple Myeloma: Final Analysis From the Phase 1 Study
2026 · Susan Bal, Myo Htut, et al. · Clinical Lymphoma Myeloma & Leukemia
P33 | Arlocabtagene Autoleucel, a Gprc5d-targeted Car T-cell Therapy for Patients With Relapsed/refractory Multiple Myeloma: Updated Phase 1 Safety and Efficacy Results in Patients With 1–3 Prior Regimens
2026 · S. Bal, M. Htut, et al. · Haematologica
PDF
Assessment of pharmacodynamic efficacy biomarkers from A phase 1, first-in-human study of arlocabtagene autoleucel (arlo-cel) in relapsed and refractory multiple myeloma (RRMM)
2025 · Safiyyah Ziyad, Kristina Jordahl, et al. · Blood
PDF
Long-term Follow-Up of a Phase 1 Study of Arlocabtagene Autoleucel (arlo-cel; BMS-986393) in Patients With Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM)
2025 · Susan Bal, Myo Htut, et al. · Clinical Lymphoma Myeloma & Leukemia
Arlocabtagene Autoleucel, a GPRC5D-Targeted CAR T-Cell Therapy for Patients With Relapsed/Refractory Multiple Myeloma: Updated Phase 1 Safety and Efficacy Results in Patients With 1–3 Prior Regimens
2025 · Susan Bal, Myo Htut, et al. · Clinical Lymphoma Myeloma & Leukemia
OA-08 Safety and Preliminary Efficacy of BMS-986393, a GPRC5D CAR T Cell Therapy, in Patients (pts) With Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1–3 Prior Regimens: Results From a Phase 1 Study
2024 · Myo Htut, Omar Nadeem, et al. · Clinical Lymphoma Myeloma & Leukemia
Validation of prototype biomarkers to identify risk factors of inflammatory adverse events (iAEs) following idecabtagene vicleucel (ide-cel) infusion in patients with relapsed and refractory multiple myeloma (RRMM) in KarMMa-3.
2024 · Sanhita Sengupta, Clara Amorosi, et al. · Journal of Clinical Oncology
Works count: 31
Citation count: 452
H-index: 8
I10-index: 7
Year
Topic
Type